MO: FY25 Deep Dive
FY25 net revenues $23.279B (-3.1%); revenues net of excise taxes $20.139B (-1.5%) — Smokeable Products full-year adjusted OCI margin expanded 180bp to 63.4%. NJOY (e-vapor) impairments totaled $2,128M in FY25 ($873M goodwill Q1 + $285M goodwill Q4 + $970M definite-lived intangible assets Q4) on illicit market headwinds. on! grew share; on PLUS launching nationally H1 2026. Capital return $7.96B (~$6.96B div + $1B buyback). 60th consecutive dividend increase. FY26 EPS guide $5.56-$5.72.
Key Takeaways
Altria closed fiscal 2025 (calendar year ended December 31, 2025) at $23.279 billion of net revenues, down 3.1% YoY — the structural decline pace consistent with cigarette volume erosion partially offset by pricing. Revenues net of excise taxes were $20.139 billion, down 1.5% YoY. The structural read in FY25 was the $2,128M NJOY (e-vapor) impairments taken across the year — $873M goodwill impairment in Q1 and $970M definite-lived intangible assets impairment plus $285M goodwill impairment in Q4 — Altria writing down its NJOY acquisition value due to "lack of meaningful reduction in illicit e-vapor volumes despite increased enforcement." Operating income reached $9.899 billion (42.5% operating margin on gross revenues, or 49.1% on revenues net of excise taxes); net income $6.95B (-38% from $11.26B FY24, distorted by both the impairments and FY24 having $2.7B Cronos / ABI mark-to-market gains); diluted EPS $4.11 (vs $6.54 FY24). Free cash flow was $9.07 billion (+5%). Capital allocation: $6.96B in dividends (+2%, the 60th consecutive annual dividend increase), $1.0B in buybacks (-71% from $3.4B FY24). Total return $7.96B. Total debt $25.71B (vs $24.93B FY24). The Smokeable Products full-year adjusted OCI grew 4% with margin expansion 180bp to 63.4% — on! nicotine pouches grew shipment volume; ON PLUS launching nationally H1 2026 with positive consumer feedback. International expansion: ON PLUS + Fumi in 7 international markets (40K+ retail locations). Sell-side coverage is 5 analysts: 3 Buy / 1 Hold / 1 Sell, consensus PT $68.60, range $63-$74. Recent activity: B of A $72→$73 (April 10), UBS $67→$74 (March 9), Barclays $57→$63 (Feb 23, sole UW); Citi $57→$65 (Feb 9). Management FY26 guide: full-year adjusted diluted EPS $5.56-$5.72 (weighted to H2, reflecting investments + NJOY ACE pause).
Main business structure
Altria reports operating segments by product category, expanded post-NJOY:
| Segment | FY25 Approx Revenue | YoY |
|---|---|---|
| Smokeable Products (cigarettes, cigars) | ~$15.5B (~77%) | Down on volume |
| Oral Tobacco Products (snus, MST, on!) | ~$2.8B (~14%) | Mid-single-digit |
| E-vapor Products (NJOY) | -$13M (negative) | ITC exclusion impact |
| Other / wine | ~$1.4B (~7%) | — |
| Total Revenue | $23.279B | -3.1% |
Smokeable Products (~77% of revenue, the cash cow)
- FY25 adjusted operating company income (OCI) >$11B
- FY25 adjusted OCI margin expanded 180bp to 63.4% (from 61.6% FY24)
- Q4 adjusted OCI declined 2.4%; margin contracted 0.8pp to 60.4% (the typical seasonal pattern)
- Domestic cigarette volumes declined (industry secular pressure)
- Marlboro retains premium-segment leadership (~59-60% premium share); discount segment has been growing on consumer down-trading
- Basic brand strategically expanded into 30,000 targeted stores; +0.4 share point sequentially
- Cigars (Middleton / Black & Mild): outperformed industry; +3.7% volume Q2 / continued growth Q4
Oral Tobacco Products (~14%, the secular growth engine)
- Q4 adjusted OCI declined 4.6%; full year +1.3%
- Q4 OCI margin contracted 5pp to 64.5% (investment in on PLUS); full year margin 67.9% (+0.1pp)
- on! nicotine pouches grew shipment volume; +10 share points YoY in Q2 commentary
- on PLUS launched in select states; national rollout H1 2026 — the FY26 catalyst
- on! brand awareness boosted by Helix activations + digital marketing
- Total segment shipment volume decreased on MST decline; on! growth partially offset
E-vapor Products (NJOY) — the FY25 disappointment
- $2,128M total impairments FY25 ($873M goodwill Q1 + $970M definite-lived intangible assets Q4 + $285M goodwill Q4) on lack of meaningful reduction in illicit e-vapor volumes despite increased enforcement
- E-vapor revenue: -$13M (negative due to ITC exclusion order impact on NJOY ACE)
- NJOY ACE redesigned product addressing JUUL patent dispute completed; in development for broader vapor portfolio
- Strategic position: enforcement-dependent, regulatory-clarity-dependent
International + Smoke-free
- ON PLUS + Fumi in 7 international markets — 40,000 retail locations
- Horizon (heated tobacco): filed PMTA + MRTPA in 2025 — pending FDA review
- KT&G collaboration for international modern oral + US non-nicotine opportunities
- ABI investment: 8.1% economic interest in Anheuser-Busch InBev; equity earnings $130M Q2 (-10% on lower ownership)
Capital Returns
- 60th consecutive annual dividend increase
- $6.96B dividends FY25
- $1.0B buybacks FY25 (down from $3.4B FY24)
- $400M remaining authorization under existing program
Customer concentration. Convenience stores + retail through wholesale distributors. No 10%+ disclosure.
Scale anchors. ~6,500 employees. Richmond VA HQ. ~$50B in branded tobacco asset base.
Key core metrics (3-year trend)
1. Revenue and operating income
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Revenue ($B) | 20.50 | 20.44 | 23.279 |
| YoY | — | -0.3% | -3.1% |
| Operating income ($B) | 11.55 | 11.24 | 9.899 |
| Operating margin | 56% | 55% | 42.5% |
The FY25 operating income reflects the $2,128M NJOY impairments taken in Q1 and Q4. Adjusted OCI (excluding special items) totaled $12.568B with a 62.4% margin on revenues net of excise taxes. The underlying tobacco margin discipline remains strong, with Smokeable Products adjusted OCI margin expanding 180bp to 63.4%.
2. Earnings
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Net income ($B) | 8.13 | 11.26 | 6.95 |
| Diluted EPS | $4.57 | $6.54 | $4.11 |
FY24 elevated net income reflected $2.7B mark-to-market gains on Cronos / ABI investments; FY25 reverted to closer-to-trend profitability with the $2,128M NJOY impairments as offset.
3. Free cash flow + capital return
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| OCF ($B) | 9.29 | 8.75 | 9.29 |
| Capex ($M) | 196 | 142 | 216 |
| FCF ($B) | 9.09 | 8.61 | 9.07 |
| Dividends ($B) | 6.78 | 6.85 | 6.96 |
| Buybacks ($B) | 1.0 | 3.4 | 1.0 |
| Total return ($B) | 7.78 | 10.25 | 7.96 |
Capital return moderated to $7.96B (vs $10.25B FY24, the all-time high) — reflecting debt deleveraging priority and reduced opportunistic buybacks. Dividend continued the streak: 60 consecutive years.
4. FY26 guidance: Full-year adjusted diluted EPS $5.56-$5.72 (weighted to H2, reflecting planned investments + NJOY ACE absent from market).
Market evaluation
Sell-side coverage (as of April 27, 2026). 5 analysts cover the stock.
| Rating | Count |
|---|---|
| Buy / Outperform / Overweight | 3 |
| Hold / Neutral | 1 |
| Sell / Underweight | 1 (Barclays) |
Price targets. Consensus $68.60, range $63 (low: Barclays, UW) to $74 (high: UBS, Buy).
Recent analyst activity (Feb-April 2026). 4 covered actions in window, all PT raises:
- B of A: $72 → $73 on April 10 — Buy maintained, +$1
- UBS: $67 → $74 on March 9 — Buy maintained, +$7, Street-high
- Barclays: $57 → $63 on Feb 23 — Underweight maintained, +$6 (lone Sell rating)
- Citi: $57 → $65 on Feb 9 — Neutral maintained, +$8
The PT pattern is uniformly positive; the lone bear (Barclays UW) at $63 is structurally cautious on smokable volume erosion + NJOY impairment risk + regulatory pressure on heated tobacco / vapor categories.
Buy-side positioning. MO is a core defensive consumer staples / dividend yield holding. ~7-8% dividend yield. Low beta. Short interest below 1.5% of float.
FY25 corporate structure: cash machine + on! growth + NJOY reset
FY25 was the year Altria's "smokable cash machine + oral tobacco secular growth + e-vapor reset" trifecta crystallized. Smokable Products ~77% of revenue with adjusted OCI margin expanding to 63.4% — the durable cash flow engine. Oral Tobacco at ~14% with on! nicotine pouches gaining share + ON PLUS national rollout in H1 2026 the secular growth engine. The $2,128M NJOY impairments are the strategic acknowledgment that the e-vapor business is not delivering on the original acquisition thesis (the illicit market remains too large + regulatory enforcement insufficient). Capital allocation continues the dividend-first model — 60th consecutive annual dividend increase; $7B+ annual return cap; ~7-8% dividend yield supports the equity story for income investors. The Q1 FY26 earnings print this week is the proximate event for measuring continued smokable margin expansion + on PLUS national launch progression + regulatory commentary on heated tobacco PMTA/MRTPA review status + tariff impact (if any) on tobacco supply chain.